Genemedicine (Biotechnology) Overview
- Year Founded
-
1992
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Genemedicine (Biotechnology) General Information
Description
Developer of bio-pharmaceutical products. The company designs gene medicines to produce sustained levels of therapeutic proteins within the body. The company develops therapeutic products for both acute and chronic use and to be administered to patients through conventional means such as intramuscular or intravenous injection, or inhalation.
Contact Information
Website
www.genemedicine.comCorporate Office
- 8301 New Trails Drive
- Spring, TX 77381
- United States
Corporate Office
- 8301 New Trails Drive
- Spring, TX 77381
- United States
Genemedicine (Biotechnology) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 19-Mar-1999 | Completed | Generating Revenue | |||
| 7. PIPE | 10-Feb-1998 | Completed | Generating Revenue | |||
| 6. PIPE | 04-Feb-1997 | Completed | Generating Revenue | |||
| 5. Grant | 15-Oct-1996 | Completed | ||||
| 4. PIPE | 06-Feb-1996 | Completed | Generating Revenue | |||
| 3. PIPE | 14-Feb-1995 | Completed | Generating Revenue | |||
| 2. IPO | 01-Jul-1994 | $13.5M | $22M | Completed | Generating Revenue | |
| 1. Early Stage VC | 17-May-1993 | $8.5M | $8.5M | Completed | Product Development |
Genemedicine (Biotechnology) Patents
Genemedicine (Biotechnology) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2000011137-A1 | Acid labile cationic amphiphiles | Inactive | 24-Aug-1998 | ||
| WO-1999047678-A2 | Interferon alpha plasmids and delivery systems, and methods of making and using the same | Inactive | 19-Mar-1998 | ||
| WO-1999031262-A2 | Needle-free injection of formulated nucleic acid molecules | Inactive | 16-Dec-1997 | ||
| WO-1999024596-A1 | Expression plasmids for multiepitope nucleic acid-based vaccines | Inactive | 12-Nov-1997 | ||
| WO-1999012945-A2 | Hydrophobic glycosylamine derivatives, compositions, and methods for use | Inactive | 08-Sep-1997 | C12N15/87 |
Genemedicine (Biotechnology) Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Abingworth | Venture Capital | Minority | ||
| CHL Medical Partners | Venture Capital | Minority | ||
| New Enterprise Associates | Venture Capital | Minority | ||
| Roche Boehringer Mannheim Diagnostics | Corporation | Minority | ||
| The Bioscience Investment Trust | Limited Partner | Minority |
Genemedicine (Biotechnology) FAQs
-
When was Genemedicine (Biotechnology) founded?
Genemedicine (Biotechnology) was founded in 1992.
-
Where is Genemedicine (Biotechnology) headquartered?
Genemedicine (Biotechnology) is headquartered in Spring, TX.
-
What industry is Genemedicine (Biotechnology) in?
Genemedicine (Biotechnology)’s primary industry is Biotechnology.
-
Is Genemedicine (Biotechnology) a private or public company?
Genemedicine (Biotechnology) is a Private company.
-
What is Genemedicine (Biotechnology)’s current revenue?
The current revenue for Genemedicine (Biotechnology) is .
-
How much funding has Genemedicine (Biotechnology) raised over time?
Genemedicine (Biotechnology) has raised $35.2M.
-
Who are Genemedicine (Biotechnology)’s investors?
Abingworth, CHL Medical Partners, New Enterprise Associates, Roche Boehringer Mannheim Diagnostics, and The Bioscience Investment Trust are 5 of 6 investors who have invested in Genemedicine (Biotechnology).
-
When was Genemedicine (Biotechnology) acquired?
Genemedicine (Biotechnology) was acquired on 19-Mar-1999.
-
Who acquired Genemedicine (Biotechnology)?
Genemedicine (Biotechnology) was acquired by Megabios.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process